Evidence map›Paper›PMID 40104151›Full record

ArticleMolecular therapy. Methods & clinical development2025

Immune-driven gene expression loss following intramuscular AAV delivery to non-human primates is only transient.

Malo Journou, Marie Devaux, Nicolas Jaulin, Virginie Pichard, Mercedes Segovia, Aurélie Moreau, Johanne Le Duff, Maria Cristina Cuturi, Mickaël Guilbaud, Oumeya Adjali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The curious case of AAV immunology.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Malo JournouINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Marie DevauxINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Nicolas JaulinINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Virginie PichardINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Mercedes SegoviaINSERM UMR 1064, ITUN - Institut de Transplantation Urologie Nephrologie, CHU de Nantes, Center of Research in Transplantation and Immunology, Université de Nantes, 44200 Nantes, France.
Aurélie MoreauINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Johanne Le DuffINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Maria Cristina CuturiINSERM UMR 1064, ITUN - Institut de Transplantation Urologie Nephrologie, CHU de Nantes, Center of Research in Transplantation and Immunology, Université de Nantes, 44200 Nantes, France.
Mickaël GuilbaudINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.
Oumeya AdjaliINSERM UMR 1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, CHU de Nantes, 44200 Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant adeno-associated virus (rAAV) vectors stand out as highly promising for

Indexed as

AAVgene transferimmune responseimmunomodulationintramuscularnon-human primatetransitory lossTregs

Identifiers

PMID40104151
PMCPMC11914520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.